Search research articles
Contact Us
Filters
Showing results (121-130 of 134) with videos related to
Page
of 14
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
JCO Precision Oncology
|
August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab
Alberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Lancet (London, England)
|
January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2025
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Husam A Alqaisi, David E Cohn, Jing-Yi Chern, et al.
Nature Communications
|
August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
S Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
NPJ Precision Oncology
|
February 13, 2026
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab
Eric Y Stutheit-Zhao, Yongqi Zhong, Collin A Melton, et al.
European Journal of Human Genetics : EJHG
|
January 29, 2026
Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium
Kirsten M Farncombe, Julia A Sobotka, Melyssa Aronson, et al.
The New England Journal of Medicine
|
February 9, 2022
Survival with Cemiplimab in Recurrent Cervical Cancer
Krishnansu S Tewari, Bradley J Monk, Ignace Vergote, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2019
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
Derek L Clouthier, Scott C Lien, S Y Cindy Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2017
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach
Goli Samimi, Marcus Q Bernardini, Lawrence C Brody, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 134) with videos related to
Sort By:
Page
of 14
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
JCO Precision Oncology
|
August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab
Alberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Lancet (London, England)
|
January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2025
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Husam A Alqaisi, David E Cohn, Jing-Yi Chern, et al.
Nature Communications
|
August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
S Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
NPJ Precision Oncology
|
February 13, 2026
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab
Eric Y Stutheit-Zhao, Yongqi Zhong, Collin A Melton, et al.
European Journal of Human Genetics : EJHG
|
January 29, 2026
Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium
Kirsten M Farncombe, Julia A Sobotka, Melyssa Aronson, et al.
The New England Journal of Medicine
|
February 9, 2022
Survival with Cemiplimab in Recurrent Cervical Cancer
Krishnansu S Tewari, Bradley J Monk, Ignace Vergote, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2019
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
Derek L Clouthier, Scott C Lien, S Y Cindy Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2017
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach
Goli Samimi, Marcus Q Bernardini, Lawrence C Brody, et al.
Page
of 14